Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Evaluation of primary bone lymphoma and the importance of positron emission tomography.

Cıraklı A, Elli M, Dabak N, Canbaz Tosun F, Dağdemir A, Cıraklı S.

Acta Orthop Traumatol Turc. 2014;48(3):371-8. doi: 10.3944/AOTT.2014.3014.

PMID:
24901932
2.
3.

Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?

Mittal BR, Manohar K, Malhotra P, Das R, Kashyap R, Bhattacharya A, Varma N, Varma S.

Leuk Lymphoma. 2011 Nov;52(11):2111-6. doi: 10.3109/10428194.2011.593273. Epub 2011 Jul 12.

PMID:
21745169
4.

The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.

Sioka C.

Eur J Pediatr. 2013 Jun;172(6):733-8. doi: 10.1007/s00431-013-1993-8. Epub 2013 Apr 5. Review.

PMID:
23559330
5.

Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.

Pelosi E, Pregno P, Penna D, Deandreis D, Chiappella A, Limerutti G, Vitolo U, Mancini M, Bisi G, Gallo E.

Radiol Med. 2008 Jun;113(4):578-90. doi: 10.1007/s11547-008-0264-7. Epub 2008 Apr 14. English, Italian.

PMID:
18414808
6.

New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.

Cheson BD.

Radiol Clin North Am. 2008 Mar;46(2):213-23, vii. doi: 10.1016/j.rcl.2008.03.003.

PMID:
18619377
7.

Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study.

Pelosi E, Penna D, Douroukas A, Bellò M, Amati A, Arena V, Passera R, Bisi G.

Q J Nucl Med Mol Imaging. 2011 Aug;55(4):469-75. Epub 2010 Dec 9.

PMID:
21150862
8.

Epiphyseal presentation of non-Hodgkin's lymphoma of bone in two pediatric patients--one with primary lymphoma of bone.

Fox MG, Marti JK, Bachmann KR, LeGallo RD, Foster WC.

Skeletal Radiol. 2015 Apr;44(4):587-95. doi: 10.1007/s00256-014-2010-7. Epub 2014 Sep 26.

PMID:
25256753
9.

The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma.

Muslimani AA, Farag HL, Francis S, Spiro TP, Chaudhry AA, Chan VC, Taylor HC, Daw HA.

Am J Clin Oncol. 2008 Oct;31(5):409-12. doi: 10.1097/COC.0b013e318168d90b.

PMID:
18838874
10.

Primary multifocal osseous lymphoma in a child.

Sato TS, Ferguson PJ, Khanna G.

Pediatr Radiol. 2008 Dec;38(12):1338-41. doi: 10.1007/s00247-008-0964-0. Epub 2008 Sep 9.

PMID:
18779959
11.

Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.

Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e647-54. doi: 10.1016/j.ijrobp.2012.01.060. Epub 2012 May 18.

PMID:
22607911
12.
13.

Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.

Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ.

Cancer. 2002 Feb 15;94(4):879-88.

14.

Non-Hodgkin's lymphoma of the bone and the liver without lymphadenopathy revealed on FDG-PET/CT.

Cheng G, Servaes S, Chamroonrat W, Li J, Zhuang H.

Clin Imaging. 2010 Nov-Dec;34(6):476-9. doi: 10.1016/j.clinimag.2009.11.013.

PMID:
21092880
15.

FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.

Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G.

Q J Nucl Med Mol Imaging. 2008 Mar;52(1):9-16.

16.

Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma.

Adams HJ, Kwee TC.

J Clin Oncol. 2015 Apr 1;33(10):1217. doi: 10.1200/JCO.2014.58.7360. Epub 2015 Feb 17. No abstract available.

PMID:
25691675
17.

Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?

Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KD, von Schulthess GK, Goerres GW.

Radiology. 2004 Sep;232(3):823-9. Epub 2004 Jul 23.

PMID:
15273335
18.

The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.

Schrepfer T, Haerle SK, Strobel K, Schaefer N, Hälg RA, Huber GF.

Laryngoscope. 2010 May;120(5):937-44. doi: 10.1002/lary.20843.

PMID:
20422687
19.

Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients.

Spaepen K, Stroobants S, Verhoef G, Mortelmans L.

Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S97-105. Epub 2003 Apr 23. Review.

PMID:
12709831
20.

Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study.

Bakhshi S, Radhakrishnan V, Sharma P, Kumar R, Thulkar S, Vishnubhatla S, Dhawan D, Malhotra A.

Radiology. 2012 Mar;262(3):956-68. doi: 10.1148/radiol.11110936.

PMID:
22357895

Supplemental Content

Support Center